Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.81
Shares Outstanding175.6M
Average Volume (10 days)1.2M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.88)
Sales (TTM)$7.15
Book Value (MRQ)$16.02
Cash Flow (TTM)($0.14)
Cash (MRQ)$7.18

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy15
 
Buy2
 
Hold4
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Robert J. Hombach
3,180
Acquire
Sep 29, 2017
Robert A. Baffi
EVP, Technical Operations
(15,500)
Sell
Sep 28, 2017
Robert A. Baffi
EVP, Technical Operations
(2,915)
Sell
Sep 28, 2017
Jeff Ajer
EVP, Chief Commercial Officer
(1,355)
Sell
Sep 22, 2017
Jeff Ajer
EVP, Chief Commercial Officer
(2,166)
Sell
Sep 22, 2017

Recent SEC Filings

CT ORDER
Nov 17, 2017
Amended Quarterly Financials
Nov 13, 2017
Quarterly Financials
Oct 31, 2017
Company Events
Oct 26, 2017
Amended Insider Buy/Sell
Oct 13, 2017

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information